Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: Awareness warranted for 2017/18 season

Rondy, M.; Gherasim, A.; Casado, I.; Launay, O.; Rizzo, C.; Pitigoi, D.; Mickiene, A.; Marbus, S. D.; Machado, A.; Syrjanen, R. K.; Pem-Novose, I.; Horvath, J. K.; Larrauri, A.; Castilla, J.; Vanhems, P.; Alfonsi, V.; Ivanciuc, A. E.; Kuliese, M.; Van Gageldonk-Lafeber, R.; Gomez, V.; Ikonen, N.; Lovric, Z.; Ferenczi, A.; Moren, A.; Pozo, F.; Garcia, M.; Latorre, M.; Omenaca, M.; Oribe Amores, M.; Munoz, N.; Cilla, G.; Fernandino, L.; Martinez-Baz, I.; Navascues, A.; Perez-Garcia, A.; Aguinaga, A.; Ezpeleta, C.; Bella, A.; Appelgren, E. C.; Castrucci, M. R.; Puzelli, S.; Chironna, M.; Germinario, C.; Ansaldi, F.; Manini, I.; Montomoli, E.; Lupulescu, E.; Lazar, M.; Mihai, M. E.; Cherciu, C. M.; Dinu, S.; Tecu, C.; Nitescu, M.; Bacruban, R.; Azamfire, D.; Dumitrescu, A.; Ianosik, E.; Ceausu, E.; Popescu, C. P.; Florescu, S. A.; Tardei, G.; Bejan, C.; Teodor, A.; Juganariu, G.; Plesca, C.; Duca, E.; Lenzi, N.; Lesieur, Z.; Loulergue, P.; Galtier, F.; Agostini, C.; Ray, M.; Merle, C.; Foulongne, V.; Lina, B.; Laine, F.; De Guibert, S.; Lagathu, G.; Tattevin, P.; Jouneau, S.; Esvant, A.; Le Gallou, T.; Carrat, F.; Mawuvi, G.; Chau, F.; Nohynek, H.; Haveri, A.; Gefenaite, G.; Velyvyte, D.; Jancoriene, L.; Zablockiene, B.; Ambrozaitis, A.; Grimalauskaite, R.; Damuleviciene, G.; Lesauskaite, V.; Bagdonas, A.; Nunes, B.; Kislaya, I.; Rodrigues, A. P.; Gomes, V.; Corte-Real, R.; Pocas, J.; Peres, M. J.; Bernard, K.; Kurecic-Filipovic, S.; Visekruna Vucina, V.; Topic, A.; Papic, N.; Budimir, J.; Oroszi, B.; Meijer, A.; Van Der Hoek, W.; Schneeberger, P. M.

doi:10.2807/1560-7917.ES.2017.22.41.17-00645

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65–79-year-olds and 13% (95% CI: −15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

Rondy, M., Gherasim, A., Casado, I., Launay, O., Rizzo, C., Pitigoi, D., et al. (2017). Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: Awareness warranted for 2017/18 season. EUROSURVEILLANCE, 22(41), 1-6 [10.2807/1560-7917.ES.2017.22.41.17-00645].